Banka Bioloo Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 13, 2025, 8:18 pm

Competitors of Banka Bioloo Ltd

All Competitor Stocks of Banka Bioloo Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:05 pm

Below is a detailed analysis of the quarterly data for Banka Bioloo Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 11.14 Cr.. The value appears to be declining and may need further review. It has decreased from 14.84 Cr. (Mar 2025) to 11.14 Cr., marking a decrease of 3.70 Cr..
• For Expenses, as of Jun 2025, the value is 10.80 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 15.01 Cr. (Mar 2025) to 10.80 Cr., marking a decrease of 4.21 Cr..
• For Operating Profit, as of Jun 2025, the value is 0.34 Cr.. The value appears strong and on an upward trend. It has increased from -0.17 Cr. (Mar 2025) to 0.34 Cr., marking an increase of 0.51 Cr..
• For OPM %, as of Jun 2025, the value is 3.05%. The value appears strong and on an upward trend. It has increased from -1.15% (Mar 2025) to 3.05%, marking an increase of 4.20%.
• For Other Income, as of Jun 2025, the value is 1.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Mar 2025) to 1.06 Cr., marking an increase of 1.03 Cr..
• For Interest, as of Jun 2025, the value is 0.89 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.03 Cr. (Mar 2025) to 0.89 Cr., marking a decrease of 0.14 Cr..
• For Depreciation, as of Jun 2025, the value is 0.64 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.66 Cr. (Mar 2025) to 0.64 Cr., marking a decrease of 0.02 Cr..
• For Profit before tax, as of Jun 2025, the value is -0.13 Cr.. The value appears strong and on an upward trend. It has increased from -1.83 Cr. (Mar 2025) to -0.13 Cr., marking an increase of 1.70 Cr..
• For Tax %, as of Jun 2025, the value is -100.00%. The value appears to be improving (decreasing) as expected. It has decreased from -12.02% (Mar 2025) to -100.00%, marking a decrease of 87.98%.
• For Net Profit, as of Jun 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from -1.61 Cr. (Mar 2025) to 0.01 Cr., marking an increase of 1.62 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears strong and on an upward trend. It has increased from -1.49 (Mar 2025) to 0.01, marking an increase of 1.50.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:27 pm

Growth

Last Updated: September 5, 2025, 12:35 am

Balance Sheet

Last Updated: June 16, 2025, 12:24 pm

Below is a detailed analysis of the balance sheet data for Banka Bioloo Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 10.87 Cr.. The value appears strong and on an upward trend. It has increased from 10.85 Cr. (Mar 2024) to 10.87 Cr., marking an increase of 0.02 Cr..
• For Reserves, as of Mar 2025, the value is 20.64 Cr.. The value appears to be declining and may need further review. It has decreased from 28.87 Cr. (Mar 2024) to 20.64 Cr., marking a decrease of 8.23 Cr..
• For Borrowings, as of Mar 2025, the value is 34.73 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 25.91 Cr. (Mar 2024) to 34.73 Cr., marking an increase of 8.82 Cr..
• For Other Liabilities, as of Mar 2025, the value is 15.92 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.80 Cr. (Mar 2024) to 15.92 Cr., marking an increase of 4.12 Cr..
• For Total Liabilities, as of Mar 2025, the value is 82.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 77.43 Cr. (Mar 2024) to 82.16 Cr., marking an increase of 4.73 Cr..
• For Fixed Assets, as of Mar 2025, the value is 15.86 Cr.. The value appears strong and on an upward trend. It has increased from 15.39 Cr. (Mar 2024) to 15.86 Cr., marking an increase of 0.47 Cr..
• For CWIP, as of Mar 2025, the value is 7.64 Cr.. The value appears strong and on an upward trend. It has increased from 6.51 Cr. (Mar 2024) to 7.64 Cr., marking an increase of 1.13 Cr..
• For Investments, as of Mar 2025, the value is 0.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.02 Cr. (Mar 2024) to 0.04 Cr., marking an increase of 0.02 Cr..
• For Other Assets, as of Mar 2025, the value is 58.62 Cr.. The value appears strong and on an upward trend. It has increased from 55.51 Cr. (Mar 2024) to 58.62 Cr., marking an increase of 3.11 Cr..
• For Total Assets, as of Mar 2025, the value is 82.16 Cr.. The value appears strong and on an upward trend. It has increased from 77.43 Cr. (Mar 2024) to 82.16 Cr., marking an increase of 4.73 Cr..

However, the Borrowings (34.73 Cr.) are higher than the Reserves (20.64 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Banka Bioloo Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -8.21. This value is below the healthy minimum of 5. It has decreased from -0.60 (Mar 24) to -8.21, marking a decrease of 7.61.
• For Diluted EPS (Rs.), as of Mar 25, the value is -8.21. This value is below the healthy minimum of 5. It has decreased from -0.59 (Mar 24) to -8.21, marking a decrease of 7.62.
• For Cash EPS (Rs.), as of Mar 25, the value is -5.89. This value is below the healthy minimum of 3. It has decreased from 1.42 (Mar 24) to -5.89, marking a decrease of 7.31.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.98. It has decreased from 36.62 (Mar 24) to 28.98, marking a decrease of 7.64.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.98. It has decreased from 36.62 (Mar 24) to 28.98, marking a decrease of 7.64.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 49.82. It has increased from 46.09 (Mar 24) to 49.82, marking an increase of 3.73.
• For PBDIT / Share (Rs.), as of Mar 25, the value is -2.34. This value is below the healthy minimum of 2. It has decreased from 3.80 (Mar 24) to -2.34, marking a decrease of 6.14.
• For PBIT / Share (Rs.), as of Mar 25, the value is -4.67. This value is below the healthy minimum of 0. It has decreased from 1.78 (Mar 24) to -4.67, marking a decrease of 6.45.
• For PBT / Share (Rs.), as of Mar 25, the value is -8.42. This value is below the healthy minimum of 0. It has decreased from -0.49 (Mar 24) to -8.42, marking a decrease of 7.93.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -8.22. This value is below the healthy minimum of 2. It has decreased from -0.59 (Mar 24) to -8.22, marking a decrease of 7.63.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -8.20. This value is below the healthy minimum of 2. It has decreased from -0.60 (Mar 24) to -8.20, marking a decrease of 7.60.
• For PBDIT Margin (%), as of Mar 25, the value is -4.69. This value is below the healthy minimum of 10. It has decreased from 8.24 (Mar 24) to -4.69, marking a decrease of 12.93.
• For PBIT Margin (%), as of Mar 25, the value is -9.36. This value is below the healthy minimum of 10. It has decreased from 3.86 (Mar 24) to -9.36, marking a decrease of 13.22.
• For PBT Margin (%), as of Mar 25, the value is -16.89. This value is below the healthy minimum of 10. It has decreased from -1.08 (Mar 24) to -16.89, marking a decrease of 15.81.
• For Net Profit Margin (%), as of Mar 25, the value is -16.49. This value is below the healthy minimum of 5. It has decreased from -1.30 (Mar 24) to -16.49, marking a decrease of 15.19.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -16.45. This value is below the healthy minimum of 8. It has decreased from -1.30 (Mar 24) to -16.45, marking a decrease of 15.15.
• For Return on Networth / Equity (%), as of Mar 25, the value is -28.28. This value is below the healthy minimum of 15. It has decreased from -1.64 (Mar 24) to -28.28, marking a decrease of 26.64.
• For Return on Capital Employeed (%), as of Mar 25, the value is -11.46. This value is below the healthy minimum of 10. It has decreased from 3.71 (Mar 24) to -11.46, marking a decrease of 15.17.
• For Return On Assets (%), as of Mar 25, the value is -10.85. This value is below the healthy minimum of 5. It has decreased from -0.84 (Mar 24) to -10.85, marking a decrease of 10.01.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.37. This value is within the healthy range. It has increased from 0.27 (Mar 24) to 0.37, marking an increase of 0.10.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.09. This value exceeds the healthy maximum of 1. It has increased from 0.62 (Mar 24) to 1.09, marking an increase of 0.47.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.67. It has decreased from 0.70 (Mar 24) to 0.67, marking a decrease of 0.03.
• For Current Ratio (X), as of Mar 25, the value is 1.41. This value is below the healthy minimum of 1.5. It has decreased from 1.95 (Mar 24) to 1.41, marking a decrease of 0.54.
• For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has decreased from 1.62 (Mar 24) to 1.25, marking a decrease of 0.37.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.69. This value is within the healthy range. It has increased from 4.43 (Mar 24) to 7.69, marking an increase of 3.26.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is -0.67. This value is below the healthy minimum of 3. It has decreased from 1.67 (Mar 24) to -0.67, marking a decrease of 2.34.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1.29. This value is below the healthy minimum of 3. It has decreased from 0.73 (Mar 24) to -1.29, marking a decrease of 2.02.
• For Enterprise Value (Cr.), as of Mar 25, the value is 108.47. It has decreased from 123.33 (Mar 24) to 108.47, marking a decrease of 14.86.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 2.47 (Mar 24) to 2.00, marking a decrease of 0.47.
• For EV / EBITDA (X), as of Mar 25, the value is -42.62. This value is below the healthy minimum of 5. It has decreased from 29.93 (Mar 24) to -42.62, marking a decrease of 72.55.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.45, marking a decrease of 0.57.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Price / BV (X), as of Mar 25, the value is 2.50. This value is within the healthy range. It has decreased from 2.55 (Mar 24) to 2.50, marking a decrease of 0.05.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.45, marking a decrease of 0.57.
• For EarningsYield, as of Mar 25, the value is -0.11. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 24) to -0.11, marking a decrease of 0.10.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness